Vanguard Group
KAPA

Vanguard Group’s Kairos Pharma KAPA Stock Holding History

Vanguard Group’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$93.6K Hold
131,828
– – ﹤0.01% 4185
2025
Q3 		$154K Buy
+131,828
New +$151K ﹤0.01% 4166

Other funds holding KAPA

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group's KAPA Position: Q4 2025 in Review

Vanguard Group held its Kairos Pharma (KAPA) position steady in Q4 2025 at 131,828 shares worth $93.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4185.

Vanguard Group first reported a position in KAPA in Q3 2025 and has held it in 2 quarters since. The position peaked at $154K in Q3 2025. 14 funds tracked by Wall St. Rank hold KAPA as of Q4 2025.

  • Vanguard Group held 131,828 shares of Kairos Pharma worth $93.6K as of Q4 2025.
  • Vanguard Group left its Kairos Pharma share count unchanged in Q4 2025.
  • Kairos Pharma made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4185 holding.
  • Vanguard Group first reported a position in Kairos Pharma in Q3 2025 and has held it in 2 quarters since.
  • Vanguard Group's Kairos Pharma position peaked at $154K in Q3 2025.
  • 14 funds tracked by Wall St. Rank held Kairos Pharma as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.